This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Vertex Pharmaceuticals, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Kevin B Daniel: Innovator in APOL1 Inhibitors
Introduction
Kevin B Daniel is a notable inventor based in Boston, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors targeting APOL1. His work is crucial in addressing various diseases, including pancreatic cancer and kidney diseases.
Latest Patents
Kevin B Daniel holds a patent for "Inhibitors of APOL1 and methods of using same." This patent encompasses a range of compounds, including tautomers, deuterated derivatives, and pharmaceutically acceptable salts. The disclosed methods focus on treating APOL1-mediated diseases, such as focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD). He has 1 patent to his name.
Career Highlights
Kevin is currently employed at Vertex Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His work is instrumental in developing therapies that can significantly improve patient outcomes in serious health conditions.
Collaborations
One of his notable coworkers is Leslie A Dakin, with whom he collaborates on various projects within the company.
Conclusion
Kevin B Daniel's contributions to the field of medicine through his innovative patents and work at Vertex Pharmaceuticals, Inc. highlight his commitment to advancing healthcare solutions. His research on APOL1 inhibitors is paving the way for new treatments for critical diseases.